ALK obtains European approval for its house dust mite sublingual allergy immunotherapy
ALK announced it has successfully completed the registration procedure for its house dust mite sublingual allergy immunotherapy tablet in 11 European countries. HDM SLIT-tablet is indicated in adult patients (18-65 years) diagnosed by a clinical history and by a positive test for HDM sensitisation. August 31, 2015